Leerink Partners analyst Daina Graybosch predicts BioNTech's recent 21% rally will fade, despite Moderna and Merck's Phase 3 trial success for a melanoma therapy. She argues investors will absorb poor read-through for BioNTech, whose iNEST program has been negatively impacted by prior negative data.